Stryker (NYSE:SYK) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Stryker (NYSE:SYK) posted its quarterly earnings results on Tuesday. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14, Zacks reports. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same quarter in the previous year, the company earned $3.46 earnings per share. Stryker updated its FY 2025 guidance to 13.450-13.700 EPS.

Stryker Stock Performance

Shares of SYK stock opened at $394.92 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The stock has a market cap of $150.55 billion, a PE ratio of 42.33, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95. The stock has a 50-day moving average of $376.32 and a 200-day moving average of $361.59. Stryker has a one year low of $310.74 and a one year high of $406.19.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. Stryker’s dividend payout ratio is 36.01%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SYK. Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $425.00 price objective on shares of Stryker in a research report on Tuesday, January 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price objective on shares of Stryker in a research report on Tuesday, January 7th. Evercore ISI raised their price objective on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Finally, BTIG Research lifted their price target on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $405.80.

Insider Activity

In related news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.50% of the stock is currently owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.